Companies / NX1

NEXALIS THERAPEUTICS LTD

ASX:NX1Pharmaceuticals, Biotechnology & Life Sciences
253.0M shares on issueASX (delayed) · as of 28 July 2026$0.011price · delayed$2.8Mmarket cap · indicative
C
Dilution grade

Runway under 2 quarters; options/rights overhang 30% of shares; 1 cash raise in 24 months

Cash runway-0.3 quarters of funding
Share-count growth (24m)0.3%
Raise cadence (24m)1 cash raise
Options & rights overhang30.2% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

NEXALIS THERAPEUTICS LTD's ordinary share count was 253M as of February 2026, a 0.3% change between February 2026 and February 2026. The company raised capital once in the 24‑month window for total proceeds of A$150K, most recently a A$150K placement in February 2026. Options and rights could convert into 76M new shares, equal to 30.2% of the current share count, with 0% in the money and the nearest expiry in December 2026. At the March 2026 quarter the company reported A$-137K in available cash, equivalent to -0.3 quarters of cash cover. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
30.2%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
-0.3 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 253.0M per ASX (delayed) (28 July 2026).
252.4M252.6M252.9MFeb 26May 26July 26Cash raise · 17 Feb 2026

Cash runway

-0.3 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$-137k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
14 July 20263G · unquotedORDINARY FULLY PAID253.0MAppendix 3G
14 July 20263H · cancellationNX1 : ORDINARY FULLY PAID253.0MAppendix 3H
22 Feb 20262A · quoted issueNX1 : ORDINARY FULLY PAID253.0MAppendix 2A
17 Feb 20263G · unquotedORDINARY FULLY PAID246.3MAppendix 3G
17 Feb 20263G · unquotedORDINARY FULLY PAID246.3MAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$150k
Placement
17 Feb 2026 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

30.2%
Total overhang · of current shares
0.0%
In the money · at current price
76.5M
Potential new shares
Dec 2026
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
14 July 2026Sean WilliamsOther2.6M——3Y notice
14 July 2026Darryl DaviesSell56.3M2.0M—3Y notice
17 Feb 2026Sean WilliamsOther———3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

14 July 2026Change of Director's Interest Notice - Sean Williams
14 July 2026Change of Director's Interest Notice - Darryl Davies
14 July 2026Notification of cessation of securities - NX1
14 July 2026Notification regarding unquoted securities - NX1
14 July 2026Issue of director share rights post shareholder approval
6 July 2026$PUpdate on Funding Facility and Clinical Program
25 June 2026Director Appointment/Resignation
29 May 20262026 AGM results
29 May 20262026 AGM slides
27 May 2026$PReinstatement to Official Quotation
27 May 2026$PBinding Letter of Intent to replace existing $53m facility
26 May 2026$PSuspension from Quotation
21 May 2026$PTrading Halt
14 May 2026Phase 1 IRX-616a Last Patient Last Dose
13 May 2026Director Appointment/Resignation
30 Apr 20262026 AGM - Sample Proxy Form
30 Apr 20262026 AGM - Access Letter
30 Apr 2026Notice of Annual General Meeting
30 Apr 2026$PMar26 Appendix 4C Cash Flow Report
30 Apr 2026$PMar26 Quarterly Activities Report

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.